Unaudited Standalone and Consolidated Financial Results for the Quarter Ended 30th June, 2026 along with Limited Review Report
RESULTS
▲ Positive Development
MEDIUM RISK
📅 Filed on BSE: 28 Jul 2026, 11:59 AM IST · BSE ID: 11cc9191-38f0-473d-8d50-2c01934a7fc2
View Original BSE Filing (PDF)
💡
In Simple Terms
The company reported a profit for the first quarter, boosted by a one-time gain from selling a business unit.
🤖 AI Summary
- Indoco Remedies Board approved Unaudited Standalone and Consolidated Financial Results for the quarter ended 30th June, 2026.
- Standalone Net Profit was Rs. 8,232 Lakhs for Q1 FY27, compared to a loss of Rs. (2,807) Lakhs in Q1 FY26.
- Consolidated Net Profit was Rs. 6,544 Lakhs for Q1 FY27, compared to a loss of Rs. (3,635) Lakhs in Q1 FY26.
- A gain of Rs. 9,734 Lakhs from the slump sale of Ophthalmic Business Division was recognized as an Exceptional Item.
- Standalone Revenue from Operations for Q1 FY27 reached Rs. 40,812 Lakhs, an increase from Rs. 38,561 Lakhs in Q1 FY26.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Standalone Revenue from Operations
40,812 Lakhs
5.84%
Standalone Profit for the period (Net Profit)
8,232 Lakhs
Not comparable — limited prior period data.
Consolidated Revenue from Operations
46,622 Lakhs
8.21%
Consolidated Profit for the period (Net Profit)
6,544 Lakhs
Not comparable — limited prior period data.
Exceptional Items (Standalone)
9,734 Lakhs
Exceptional Items (Consolidated)
9,794 Lakhs
🏢 How This Affects the Company
The slump sale of the Ophthalmic Business Division for Rs. 9,734 Lakhs marks a divestment, allowing for focus on core pharmaceutical segments. India operations revenue increased to Rs. 22,775 Lakhs standalone.
Standalone Net Profit of Rs. 8,232 Lakhs and Consolidated Net Profit of Rs. 6,544 Lakhs were significantly impacted by the exceptional gain of Rs. 9,734 Lakhs. This improved profitability metrics for the quarter.
The divestment of the Ophthalmic Business Division streamlines the company's operational structure by removing a business segment. This may lead to altered resource allocation.
The auditor noted FPP Holding LLC has a negative net worth of Rs. 3,822.60 Lakhs, indicating a material uncertainty regarding its going concern ability. Management assessed no impairment is necessary at this stage.
👥 What This Means For Shareholders
✅
Action Required
No action is required from shareholders based on this financial results filing.
👤
Who Is Affected
All shareholders are affected by the company's financial performance, with the Q1 FY27 standalone and consolidated net profits reported at Rs. 8,232 Lakhs and Rs. 6,544 Lakhs respectively.
🔍
Management Signal
Management completed the slump sale of the Ophthalmic Business Division, indicating a strategic decision to divest non-core assets and focus on other segments.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Q2 FY27 results — monitor core business profitability excluding exceptional items.
Management commentary — for strategy regarding FPP Holding LLC's negative net worth.
Revenue split between India and Outside India — assess market performance trends.
MEDIUM RISK
Negative net worth of a subsidiary (FPP Holding LLC) flagged by auditor as a material uncertainty.
💡 Investor Takeaway
Indoco Remedies reported Standalone Net Profit of Rs. 8,232 Lakhs for Q1 FY27, significantly up from a Rs. (2,807) Lakhs loss in Q1 FY26. This includes a Rs. 9,734 Lakhs exceptional gain from asset sale. Consolidated Net Profit for Q1 FY27 was Rs. 6,544 Lakhs.
⚖️ Strengths & Concerns
✅ Positives
- Standalone Revenue from Operations increased to Rs. 40,812 Lakhs in Q1 FY27 from Rs. 38,561 Lakhs in Q1 FY26, showing revenue growth.
- Recognition of Rs. 9,734 Lakhs as an Exceptional Item from the slump sale significantly boosted standalone net profit for Q1 FY27.
⚠️ Concerns
- FPP Holding LLC, a subsidiary, has a negative net worth of Rs. 3,822.60 Lakhs as of 30th June 2026, indicating material uncertainty for its going concern.
- Standalone Other Expenses remained high at Rs. 11,712 Lakhs in Q1 FY27, constituting a significant portion of total expenses.
📅 Company Track Record
Indoco Remedies previously reported Q4 FY26 Standalone Net Profit of Rs. 2,732 Lakhs. In May 2026, the company also recommended a dividend of Rs. 0.20 per share for FY26.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What was Indoco Remedies' Standalone Net Profit for Q1 FY27?
Indoco Remedies reported a Standalone Net Profit of Rs. 8,232 Lakhs for the quarter ended 30th June, 2026.
What was Indoco Remedies' Consolidated Net Profit for Q1 FY27?
Indoco Remedies' Consolidated Net Profit for the quarter ended 30th June, 2026, stood at Rs. 6,544 Lakhs.
Was there any exceptional item impacting Q1 FY27 results for Indoco Remedies?
Yes, Indoco Remedies recognized a gain of Rs. 9,734 Lakhs from the slump sale of its Ophthalmic Business Division as an Exceptional Item in Q1 FY27 standalone results.
What was Indoco Remedies' Standalone Revenue from Operations in Q1 FY27?
Indoco Remedies reported Standalone Revenue from Operations of Rs. 40,812 Lakhs for the quarter ended 30th June, 2026.
What concern did the auditors highlight regarding Indoco Remedies' subsidiaries?
The auditors highlighted that FPP Holding LLC, a subsidiary, has a negative net worth of Rs. 3,822.60 Lakhs as of 30th June 2026, indicating a material uncertainty about its going concern ability.
Questions based on this BSE filing only. For information purposes.